WO2001060174A3 - Weight loss induced by reduction in neuropeptide y level - Google Patents

Weight loss induced by reduction in neuropeptide y level

Info

Publication number
WO2001060174A3
WO2001060174A3 PCT/US2001/005316 US0105316W WO0160174A3 WO 2001060174 A3 WO2001060174 A3 WO 2001060174A3 US 0105316 W US0105316 W US 0105316W WO 0160174 A3 WO0160174 A3 WO 0160174A3
Authority
WO
WIPO (PCT)
Prior art keywords
animal
animals
weight loss
compound
expression
Prior art date
Application number
PCT/US2001/005316
Other languages
French (fr)
Other versions
WO2001060174A2 (en
Inventor
Thomas M Loftus
Craig A Townsend
Gabriele Ronnett
M Daniel Lane
Francis P Kuhajda
Original Assignee
Thomas M Loftus
Craig A Townsend
Gabriele Ronnett
M Daniel Lane
Francis P Kuhajda
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas M Loftus, Craig A Townsend, Gabriele Ronnett, M Daniel Lane, Francis P Kuhajda, Univ Johns Hopkins filed Critical Thomas M Loftus
Priority to AU2001238515A priority Critical patent/AU2001238515A1/en
Priority to EP01910959A priority patent/EP1259121A2/en
Priority to JP2001559278A priority patent/JP2003528051A/en
Priority to CA002400136A priority patent/CA2400136A1/en
Priority to US10/476,513 priority patent/US20040157918A1/en
Publication of WO2001060174A2 publication Critical patent/WO2001060174A2/en
Publication of WO2001060174A3 publication Critical patent/WO2001060174A3/en
Priority to US11/657,536 priority patent/US20070197638A1/en
Priority to US12/558,313 priority patent/US20100022639A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5755—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA levels in the animal. Compounds administered according to this invention may be inhibitors of fatty acid synthase (FAS), including substituted α-methylene-β-carboxyl-η-butyrolactones, or inhibitors of malonyl Coenzyme A decarboxylase (MCD). Preferably, the compound is administered in an amount sufficient to reduce the amount and/or duration of expression and/or secretion of NPY to levels at or below those observed for lean animals. In another preferred embodiment, the administration will reduce expression and/or secretion to levels observed for fed or satiated animals; more preferably, administration will reduce the level of NPY below that of fed animals. In a particular embodiment, this invention provides a method for inducing weight loss in an animal by administering a compound which inhibits feeding behavior in the animal. The method is particularly useful for inducing weight loss in animals deficient in expression of the hormone leptin or animals resistant to the action of leptin.
PCT/US2001/005316 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level WO2001060174A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2001238515A AU2001238515A1 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
EP01910959A EP1259121A2 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
JP2001559278A JP2003528051A (en) 2000-02-16 2001-02-16 Weight loss induced by reduced neuropeptide Y levels
CA002400136A CA2400136A1 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
US10/476,513 US20040157918A1 (en) 2001-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
US11/657,536 US20070197638A1 (en) 2000-02-16 2007-01-25 Weight loss induced by reduction in neuropeptide level
US12/558,313 US20100022639A1 (en) 2000-02-16 2009-09-11 Methods of Inducing Weight Loss

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18290100P 2000-02-16 2000-02-16
US60/182,901 2000-02-16
US20856000P 2000-06-02 2000-06-02
US60/208,560 2000-06-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/657,536 Continuation US20070197638A1 (en) 2000-02-16 2007-01-25 Weight loss induced by reduction in neuropeptide level

Publications (2)

Publication Number Publication Date
WO2001060174A2 WO2001060174A2 (en) 2001-08-23
WO2001060174A3 true WO2001060174A3 (en) 2002-04-25

Family

ID=26878528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005316 WO2001060174A2 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level

Country Status (6)

Country Link
EP (1) EP1259121A2 (en)
JP (1) JP2003528051A (en)
KR (1) KR20030016228A (en)
AU (1) AU2001238515A1 (en)
CA (1) CA2400136A1 (en)
WO (1) WO2001060174A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040082417A (en) * 2002-02-08 2004-09-24 존스 홉킨스 유니버시티 스쿨 오브 메디슨 Stimulation of cpt-1 as a means to reduce weight
AU2003248810B2 (en) * 2002-07-01 2009-08-20 Fasgen, Llc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
EP1548131A3 (en) * 2003-12-22 2005-07-27 F. Hoffmann-La Roche Ag Novel targets for obesity from skeletal muscle
EP1732572A4 (en) * 2004-03-18 2007-04-18 Fasgen Llc Control of feeding behavior by changing neuronal energy balance
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
JPH10287637A (en) * 1997-04-14 1998-10-27 Banyu Pharmaceut Co Ltd Amidine derivative
EP0945440A1 (en) * 1996-12-16 1999-09-29 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
WO1999052363A1 (en) * 1998-04-15 1999-10-21 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
EP0945440A1 (en) * 1996-12-16 1999-09-29 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
JPH10287637A (en) * 1997-04-14 1998-10-27 Banyu Pharmaceut Co Ltd Amidine derivative
WO1999052363A1 (en) * 1998-04-15 1999-10-21 Nutriceutical Technology Corporation Method of regulating appetite and metabolism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199905, Derwent World Patents Index; Class B05, AN 1999-048775, XP002191407 *

Also Published As

Publication number Publication date
EP1259121A2 (en) 2002-11-27
JP2003528051A (en) 2003-09-24
CA2400136A1 (en) 2001-08-23
WO2001060174A2 (en) 2001-08-23
AU2001238515A1 (en) 2001-08-27
KR20030016228A (en) 2003-02-26

Similar Documents

Publication Publication Date Title
PL402389A1 (en) Method for inhibiting Raf kinase activity in humans or inanimals
MXPA04009765A (en) Method of improving absorption of vitamin e by a pet animal.
EP1210940A3 (en) Antifatigue composition comprising an imidazole compound
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
IL193771A (en) Compositions having cholesteryl ester transfer protein inhibitory activity
PT1406698E (en) Lipoxin analogs as novel inhibitors of angiogenesis
MX2007005238A (en) A transmucosal veterinary composition comprising detomidine.
PL342429A1 (en) Opioidic agonistic/antagonistic combinations
WO2005027895A3 (en) Thyroid hormone analogs and methods of use in angiogenesis
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
PL1780197T3 (en) 5-substituted-2-phenylamino benzamides as mek inhibitors
TW200616621A (en) Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
ATE293691T1 (en) MYOSTATIN GENE PROMOTER AND INHIBITION OF ITS ACTIVATION
WO2005020973A3 (en) Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
GB9903403D0 (en) Substituted stilbene compounds with vascular damaging activity
WO2008030752A3 (en) Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
DE60024730D1 (en) Theanin-containing composition for the suppression of behavioral disorders of pets
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
WO2001060174A3 (en) Weight loss induced by reduction in neuropeptide y level
EP0838225A3 (en) Aqueous local anesthetic solution
CA2403352C (en) Use of comt inhibitors as analgesics
WO2002102978A3 (en) Human growth hormone antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001238515

Country of ref document: AU

Ref document number: 2400136

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 559278

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020027010680

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001910959

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910959

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027010680

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10476513

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001910959

Country of ref document: EP